The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

Arcutis Biotherapeutics Beats Q4 Estimates as Zoryve Sales Surge 84%

Canadian flag, a plasma bag, and "GRIFOLS" text on an orange background with medical equipment, microscopes, and vials.

Key Facts

1Arcutis reported Q4 2025 revenue of $127.5M, an 84% increase year-over-year.

2The company delivered a GAAP EPS beat.

Arcutis Biotherapeutics (ARQT) reported a strong financial performance for the fourth quarter of 2025, driven by a significant surge in revenue. The company’s total revenue reached $127.5 million, representing a robust 84% increase compared to the same period last year. This growth was primarily fueled by the rapid market adoption of Zoryve, which has established itself as the leading branded nonsteroidal topical treatment in its category. Furthermore, Arcutis delivered an earnings per share (EPS) beat according to GAAP standards, signaling a successful transition toward profitability. Analysts highlight the company's strong operating leverage and robust product pipeline as key drivers for future growth. As Arcutis evolves into a commercial-stage powerhouse, its fundamental outlook remains positive despite premium valuation concerns.